General Pharmacology Practice Questions

Q: What type of antagonism is observed between acetylcholine and atropine?

Competitive antagonism. **Explanation:** **1. Why Competitive Antagonism is Correct:** Acetylcholine (ACh) and Atropine compete for the same binding site on the **muscarinic receptors**. In competitive (reversible) antagonism, the antagonist binds to the receptor site, preventing the agonist from binding. This inhibition can be overcome by increasing the concentration of the agonist (ACh), which shifts the dose-response curve to the **right** without changing the maximal response ($E_{max}$). **2. Why Other Options are Incorrect:** * **Physiological Antagonism:** This occurs when two drugs act on **different receptors** to produce opposite physiological effects (e.g., Histamine causing bronchoconstriction via $H_1$ receptors vs. Adrenaline causing bronchodilation via $\beta_2$ receptors). ACh and Atropine act on the *same* receptor. * **Noncompetitive Antagonism:** Here, the antagonist binds to an allosteric site or binds irreversibly to the active site. Increasing the agonist concentration cannot overcome this block, leading to a decrease in the maximal response ($E_{max}$). **3. NEET-PG High-Yield Pearls:** * **Surmountable Blockade:** Competitive antagonism is "surmountable." * **Graph Shift:** Look for a **parallel shift to the right** in the Log Dose-Response (LDR) curve. * **Dissociation Constant ($K_d$):** In competitive antagonism, the $K_d$ (or $EC_{50}$) increases, but the efficacy remains unchanged. * **Clinical Example:** Atropine is the drug of choice for **Organophosphate poisoning** to competitively block the excess ACh at muscarinic sites.

Q: Which of the following drugs is hydrolyzed by a plasma esterase that is abnormally low in activity in about 1 in every 2500 humans?

Succinylcholine. **Explanation** The correct answer is **Succinylcholine**. This drug is a depolarizing neuromuscular blocker used for rapid sequence induction. **1. Why Succinylcholine is Correct:** Succinylcholine is rapidly metabolized by **Pseudocholinesterase** (also known as Butyrylcholinesterase or Plasma Cholinesterase). In approximately 1 in 2500 individuals, there is a genetic polymorphism resulting in **Atypical Pseudocholinesterase**. These patients cannot hydrolyze the drug efficiently, leading to a prolonged neuromuscular block and life-threatening respiratory paralysis, a condition known as **Succinylcholine Apnea**. **2. Why the Other Options are Incorrect:** * **Ethanol:** Primarily metabolized in the liver by Alcohol Dehydrogenase (ADH) and Aldehyde Dehydrogenase (ALDH). While genetic variations exist (e.g., ALDH2 deficiency in Asians), it is not an esterase-mediated process. * **Rifampicin:** A potent inducer of Cytochrome P450 enzymes. It is metabolized via hepatic deacetylation, not plasma esterases. * **Cimetidine:** A known enzyme inhibitor (CYP450) that is excreted largely unchanged in the urine; it is not subject to plasma esterase deficiency issues. **3. Clinical Pearls for NEET-PG:** * **Diagnosis:** The presence of atypical pseudocholinesterase is confirmed by the **Dibucaine Number**. Dibucaine inhibits normal enzyme activity by 80%, but atypical enzyme by only 20%. A low Dibucaine number indicates a high risk for apnea. * **Management:** If a patient develops Succinylcholine Apnea, the immediate treatment is **mechanical ventilation** until the drug wears off. Fresh frozen plasma (FFP) can theoretically provide the enzyme but is rarely used in practice. * **Other drugs** metabolized by pseudocholinesterase include Mivacurium, Cocaine, and Procaine.

Q: Which category of drugs is difficult to market and highly expensive to produce?

Orphan drugs. **Explanation:** **Orphan drugs** are the correct answer because they are intended for the treatment, prevention, or diagnosis of **rare diseases** (e.g., Gaucher’s disease, Cystic Fibrosis, or Leprosy). Because the patient population is so small, pharmaceutical companies find it commercially unviable to develop these drugs due to the high cost of R&D versus the limited potential for profit. To encourage their production, governments provide incentives like tax credits and extended patent exclusivity. **Analysis of Incorrect Options:** * **B. Rare drugs:** This is a distractor term. While orphan drugs treat rare diseases, "rare drugs" is not a formal pharmacological classification used in drug regulation. * **C. Over the counter (OTC) drugs:** These are drugs that can be sold without a prescription (e.g., Paracetamol). They are generally inexpensive to produce, have a massive market, and are highly profitable. * **D. Emergency drugs:** These are life-saving medications required for immediate use (e.g., Adrenaline, Atropine). They have a stable market demand and are standard stock in all healthcare facilities. **High-Yield Clinical Pearls for NEET-PG:** * **Definition:** In the US, an orphan disease is defined as one affecting fewer than **200,000 people**. * **Examples of Orphan Drugs:** **Digoxin immune Fab** (for digitalis toxicity), **Fomepizole** (for methanol poisoning), **Amphotericin B** (for Kala-azar in specific regions), and **Thalidomide** (for Lepra reaction). * **Regulatory Act:** The **Orphan Drug Act (1983)** was the first major legislation to provide incentives for the development of these agents.

Q: Which of the following statements is true regarding essential medicines?

Drugs to satisfy priority health needs of the population. **Explanation:** The concept of **Essential Medicines**, as defined by the World Health Organization (WHO), refers to those drugs that **satisfy the priority healthcare needs of the population**. They are selected based on disease prevalence, evidence of efficacy and safety, and comparative cost-effectiveness. 1. **Why Option C is correct:** The core philosophy behind essential medicines is to ensure that the most necessary drugs are available at all times, in adequate amounts, in appropriate dosage forms, with assured quality, and at a price the individual and the community can afford. This is a population-based approach rather than an individual-based one. 2. **Why other options are incorrect:** * **Options A & B:** While essential medicines include drugs for emergencies and serious disorders (e.g., adrenaline or insulin), the list is not *limited* to them. It also includes drugs for common ailments like primary hypertension or simple infections. * **Option D:** Orphan drugs are used to treat rare diseases. By definition, these do not meet the "priority health needs of the population" due to their low prevalence and high cost, making them the opposite of essential medicines. **High-Yield Facts for NEET-PG:** * **First WHO Model List:** Published in **1977**. * **National List of Essential Medicines (NLEM):** India’s version, periodically updated by the Ministry of Health and Family Welfare. * **Selection Criteria:** Based on the **P-drug (Personal Drug)** concept and the **EDL (Essential Drug List)**. * **Impact:** Essential medicines are intended to be available within the context of functioning health systems at all times.

Q: The immunosuppressant action of cyclosporine appears to be due to:

Inhibition of gene transcription of interleukins. **Explanation:** **Mechanism of Action (Why C is correct):** Cyclosporine is a **calcineurin inhibitor**. Under normal physiological conditions, when a T-cell is activated, intracellular calcium increases and binds to calmodulin. This complex activates **calcineurin**, a phosphatase that dephosphorylates **NFAT** (Nuclear Factor of Activated T-cells). Dephosphorylated NFAT enters the nucleus and promotes the **transcription of interleukin-2 (IL-2)** and other cytokines. Cyclosporine binds to its cytoplasmic receptor, **cyclophilin**, and this complex inhibits calcineurin. Consequently, NFAT remains phosphorylated, cannot enter the nucleus, and the gene transcription of IL-2 is inhibited, preventing T-cell proliferation. **Analysis of Incorrect Options:** * **A & D:** Cyclosporine does not activate NK cells; in fact, it suppresses the immune response. It also does not interfere with the initial recognition of antigens by T-cell receptors (TCR). * **B:** Cyclosporine acts at the cellular level to prevent the *production* of mediators (cytokines) rather than blocking the peripheral tissue response to existing inflammatory mediators (which is more characteristic of certain antihistamines or NSAIDs). **High-Yield Clinical Pearls for NEET-PG:** * **Specific Toxicity:** Nephrotoxicity is the most common and dose-limiting side effect. * **Other Side Effects:** Gingival hyperplasia, hirsutism, hypertension, and tremors (mnemonic: **6 H's** - Hyperplasia, Hirsutism, Hypertension, Hyperlipidemia, Hyperkalemia, Hepatotoxicity). * **Drug Interactions:** It is metabolized by **CYP3A4**; enzyme inhibitors (like erythromycin or ketoconazole) can increase its toxicity. * **Tacrolimus:** Another calcineurin inhibitor that binds to **FKBP-12** instead of cyclophilin but shares a similar mechanism.

Q: All of the following are involved in the detoxification of drugs EXCEPT:

Cytochrome oxidase. **Explanation:** The detoxification of drugs primarily occurs through the **Microsomal Mixed Function Oxidase (MFO) system**, located in the smooth endoplasmic reticulum of hepatocytes. **Why Cytochrome Oxidase is the Correct Answer:** **Cytochrome oxidase** (also known as Cytochrome c oxidase or Complex IV) is a key enzyme in the **Electron Transport Chain** located in the inner mitochondrial membrane. Its primary role is cellular respiration (reducing oxygen to water to produce ATP), not drug metabolism. Therefore, it is not involved in the detoxification of xenobiotics. **Analysis of Incorrect Options:** * **Cytochrome P450 (CYP450):** This is the most important component of the MFO system. It acts as the terminal oxidase that binds to the drug substrate and molecular oxygen to facilitate oxidation. * **NADPH Cytochrome P450 Reductase:** This enzyme is essential for transferring electrons from NADPH to the Cytochrome P450 molecule, allowing the catalytic cycle to proceed. * **Monooxygenase:** This is a general functional term for the MFO system. These enzymes incorporate one atom of molecular oxygen into the substrate (drug) and reduce the other atom to water. **High-Yield Clinical Pearls for NEET-PG:** * **Phase I Reactions:** Include Oxidation (most common), Reduction, and Hydrolysis. These typically make the drug more polar. * **Phase II Reactions:** Include Glucuronidation (most common), Acetylation, and Methylation. These usually result in inactivation. * **Inducers vs. Inhibitors:** CYP450 **inducers** (e.g., Rifampicin, Phenytoin) decrease the efficacy of co-administered drugs, while **inhibitors** (e.g., Ketoconazole, Erythromycin) increase the risk of toxicity. * **Non-microsomal enzymes:** Some drugs are metabolized by non-microsomal enzymes (e.g., Alcohol dehydrogenase, Xanthine oxidase); these are *not* inducible by drugs.

Q: FK-506 is used in which of the following conditions?

Organ transplant. **Explanation:** **FK-506**, also known as **Tacrolimus**, is a potent immunosuppressant belonging to the **calcineurin inhibitor** class. **Why Option A is correct:** Tacrolimus works by binding to an intracellular protein called **FK-binding protein (FKBP)**. This complex inhibits **calcineurin**, a phosphatase enzyme required for the activation of the nuclear factor of activated T-cells (NFAT). By preventing NFAT activation, it inhibits the transcription of **Interleukin-2 (IL-2)** and other cytokines, thereby suppressing T-cell proliferation. This mechanism is vital in preventing **allograft rejection** in organ transplant recipients (e.g., kidney, liver, or heart). **Why other options are incorrect:** * **B. Bronchial asthma:** Asthma is managed with bronchodilators and corticosteroids. While Tacrolimus suppresses immune responses, it is not a standard treatment for asthma. * **C. Diabetic diarrhea:** This is usually a result of autonomic neuropathy and is managed with glycemic control or symptomatic treatments like loperamide; Tacrolimus has no role here. * **D. Chemotherapeutic agent:** Tacrolimus is an immunosuppressant, not a cytotoxic drug used to kill cancer cells. **High-Yield Clinical Pearls for NEET-PG:** * **Potency:** Tacrolimus is roughly **10–100 times more potent** than Cyclosporine. * **Side Effects:** Unlike Cyclosporine, Tacrolimus does **not** cause hirsutism or gum hyperplasia. However, it has a higher incidence of **post-transplant diabetes mellitus (PTDM)** and neurotoxicity (tremors). * **Topical Use:** Tacrolimus ointment is highly effective for **Atopic Dermatitis**. * **Metabolism:** It is metabolized by **CYP3A4**; therefore, grapefruit juice can increase its toxicity.

Q: Cyclosporine acts by decreasing the production of which of the following interleukins?

IL-2. ### Explanation **Mechanism of Action (Why B is correct):** Cyclosporine is a potent immunosuppressant that acts as a **Calcineurin Inhibitor**. Under normal physiological conditions, when a T-cell is activated, intracellular calcium increases and binds to calmodulin. This complex activates **calcineurin**, a phosphatase that dephosphorylates **NFAT** (Nuclear Factor of Activated T-cells). Dephosphorylated NFAT enters the nucleus to promote the transcription of various cytokines, most importantly **Interleukin-2 (IL-2)**. Cyclosporine binds to an intracellular protein called **Cyclophilin**. The resulting Cyclosporine-Cyclophilin complex inhibits calcineurin, preventing the dephosphorylation of NFAT. This leads to a profound **decrease in IL-2 production**, which is the primary driver for T-cell proliferation and differentiation. **Analysis of Incorrect Options:** * **A (IL-1):** Primarily produced by macrophages and monocytes. While cyclosporine has some indirect effects on macrophages, its primary target is the T-cell signaling pathway. * **C (IL-6) & D (IL-8):** These are pro-inflammatory cytokines involved in the acute phase response and neutrophil chemotaxis, respectively. They are not the primary targets of calcineurin inhibitors. **High-Yield NEET-PG Pearls:** * **Drug of Choice:** Cyclosporine is used for GVHD prophylaxis and organ transplant rejection. * **Metabolism:** Metabolized by **CYP3A4**; avoid grapefruit juice (inhibitor). * **Side Effects (High Yield):** "The 4 H's" — **H**irsutism, **H**yperplasia of gums (gingival), **H**ypertension, and **H**yperlipidemia. * **Nephrotoxicity:** This is the most common and dose-limiting side effect. * **Comparison:** Unlike Tacrolimus (which binds to FKBP-12), Cyclosporine binds to Cyclophilin, but both inhibit Calcineurin.

Q: Which one of the following medications is approved for ripening of an unfavorable cervix at or near term in a pregnant patient?

Dinoprostone. **Explanation:** **Dinoprostone (Option C)** is the correct answer. It is a synthetic analogue of **Prostaglandin E2 (PGE2)**. In obstetrics, PGE2 plays a critical role in "cervical ripening"—the process of softening, thinning (effacement), and dilating the cervix. It acts by stimulating collagenase activity, which breaks down the collagen network in the cervix, and by increasing intracellular calcium to induce uterine contractions. It is FDA-approved for this purpose at or near term. **Analysis of Incorrect Options:** * **Alprostadil (Option A):** This is **PGE1**. Its primary clinical uses include maintaining the patency of the *ductus arteriosus* in neonates with congenital heart defects and treating erectile dysfunction. * **Ergonovine (Option B):** An ergot alkaloid used primarily for **Postpartum Hemorrhage (PPH)**. It causes forceful, tetanic uterine contractions and is strictly contraindicated *before* delivery as it can cause fetal hypoxia or uterine rupture. * **Terbutaline (Option D):** A $\beta_2$-agonist used as a **tocolytic** (uterine relaxant). It is used to *delay* preterm labor, not to induce or ripen the cervix. **High-Yield NEET-PG Pearls:** * **Misoprostol (PGE1 analogue):** Also used for cervical ripening and induction of labor (off-label in many regions), but Dinoprostone is the classic "approved" choice for ripening. * **Carboprost (15-methyl PGF2$\alpha$):** Used for refractory PPH; contraindicated in asthmatics due to bronchoconstriction. * **Bishop Score:** Used to assess the "favorability" of the cervix before induction; a score of $\leq 6$ usually indicates the need for ripening agents like Dinoprostone.

Q: A reasonable explanation for the therapeutic effects of ibuprofen or naproxen in primary dysmenorrhea is that these drugs are associated with which of the following?

inhibition of prostaglandin synthesis (PGE2 and PGF2a). **Explanation:** **1. Why Option A is Correct:** Primary dysmenorrhea is primarily caused by the excessive release of prostaglandins (**PGE2 and PGF2α**) from the endometrium during menstruation. These prostaglandins cause potent uterine contractions, leading to myometrial ischemia and pain. Ibuprofen and Naproxen are non-selective **Non-Steroidal Anti-inflammatory Drugs (NSAIDs)** that inhibit the enzyme **Cyclooxygenase (COX)**. By blocking COX, they reduce the synthesis of these specific prostaglandins, thereby decreasing uterine hypercontractility and providing symptomatic relief. **2. Why Other Options are Incorrect:** * **Option B:** While some COX-2 inhibitors exist (e.g., Celecoxib), Ibuprofen and Naproxen are **non-selective** inhibitors of both COX-1 and COX-2. COX-1 inhibition is actually significant in the endometrium. * **Option C:** NSAIDs do not inhibit the Lipoxygenase (LOX) pathway; therefore, they do not reduce **leukotriene** synthesis. In fact, by blocking the COX pathway, arachidonic acid may be shunted toward the LOX pathway (the basis for NSAID-exacerbated respiratory disease). * **Option D:** **Phospholipase A2** is inhibited by **Corticosteroids** (via annexin-1/lipocortin), not by NSAIDs. PLA2 is an upstream enzyme that releases arachidonic acid from membrane phospholipids. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** NSAIDs are the first-line medical treatment for primary dysmenorrhea. * **Timing:** For maximum efficacy, NSAIDs should be started at the onset of menses or 1–2 days prior. * **Specific Prostaglandin:** **PGF2α** is the most potent stimulator of uterine smooth muscle and is the primary target in dysmenorrhea management. * **Side Effect Profile:** Non-selective NSAIDs can cause gastric irritation due to the inhibition of protective COX-1 in the gastric mucosa.

Question 1

What type of antagonism is observed between acetylcholine and atropine?

Accepted Answer

Competitive antagonism

Answer

Physiological antagonism

Answer

Noncompetitive antagonism

Answer

None of the above

Question 2

Which of the following drugs is hydrolyzed by a plasma esterase that is abnormally low in activity in about 1 in every 2500 humans?

Accepted Answer

Succinylcholine

Answer

Ethanol

Answer

Rifampicin

Answer

Cimetidine

Question 3

Which category of drugs is difficult to market and highly expensive to produce?

Accepted Answer

Orphan drugs

Answer

Rare drugs

Answer

Over the counter drugs

Answer

Emergency drugs

Question 4

Which of the following statements is true regarding essential medicines?

Accepted Answer

Drugs to satisfy priority health needs of the population

Answer

Drugs for emergency conditions

Answer

Drugs for serious disorders

Answer

Newer orphan drugs

Question 5

The immunosuppressant action of cyclosporine appears to be due to:

Accepted Answer

Inhibition of gene transcription of interleukins

Answer

Activation of NK cells

Answer

Blockade of tissue responses to inflammatory mediators

Answer

Interference with antigen recognition

Question 6

All of the following are involved in the detoxification of drugs EXCEPT:

Accepted Answer

Cytochrome oxidase

Answer

NADPH cytochrome P450 reductase

Answer

Cytochrome P450

Answer

Monooxygenase

Question 7

FK-506 is used in which of the following conditions?

Accepted Answer

Organ transplant

Answer

Bronchial asthma

Answer

Diabetic diarrhea

Answer

Chemotherapeutic agent

Question 8

Cyclosporine acts by decreasing the production of which of the following interleukins?

Accepted Answer

IL-2

Answer

IL-1

Answer

IL-6

Answer

IL-8

Question 9

Which one of the following medications is approved for ripening of an unfavorable cervix at or near term in a pregnant patient?

Accepted Answer

Dinoprostone

Answer

Alprostadil

Answer

Ergonovine

Answer

Terbutaline

Question 10

A reasonable explanation for the therapeutic effects of ibuprofen or naproxen in primary dysmenorrhea is that these drugs are associated with which of the following?

Accepted Answer

inhibition of prostaglandin synthesis (PGE2 and PGF2a)

Answer

selective inhibition of COX-2

Answer

inhibition of leukotriene synthesis (LTB4)

Answer

inhibition of phospholipase A2 (PLA2)

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?